Nicox S.A. (NICXF)
NICXF Stock Price Chart
Explore Nicox S.A. interactive price chart. Choose custom timeframes to analyze NICXF price movements and trends.
NICXF Company Profile
Discover essential business fundamentals and corporate details for Nicox S.A. (NICXF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Feb 2010
Employees
28.00
Website
https://www.nicox.comCEO
Gavin M. Spencer
Description
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
NICXF Financial Timeline
Browse a chronological timeline of Nicox S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 19 Jan 2026
Upcoming earnings on 16 Oct 2025
Earnings released on 16 Jul 2025
Earnings released on 30 Apr 2025
EPS came in at -$0.28 , while revenue for the quarter reached $2.34M .
Earnings released on 21 Jan 2025
Earnings released on 17 Oct 2024
Revenue for the quarter reached $5.25M .
Earnings released on 18 Jul 2024
Earnings released on 22 Apr 2024
EPS came in at -$0.31 , while revenue for the quarter reached $5.71M .
Earnings released on 18 Mar 2024
Earnings released on 30 Jun 2023
EPS came in at -$0.00 , while revenue for the quarter reached $866.50 .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 , while revenue for the quarter reached $866.50 .
Earnings released on 20 Mar 2023
EPS came in at -$0.25 , while revenue for the quarter reached $1.93M .
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $920.50 .
Earnings released on 16 Sept 2022
EPS came in at -$0.41 , while revenue for the quarter reached $1.50M .
Earnings released on 28 Apr 2022
EPS came in at -$0.91 falling short of the estimated -$0.47 by -95.12%, while revenue for the quarter reached $6.72M , beating expectations by +73.85%.
Earnings released on 27 Sept 2021
EPS came in at -$0.37 surpassing the estimated -$0.40 by +8.82%, while revenue for the quarter reached $2.00M , missing expectations by -19.88%.
Earnings released on 1 Mar 2021
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $12.86M , beating expectations by +0.13%.
Earnings released on 10 Sept 2020
EPS came in at -$0.49 surpassing the estimated -$0.52 by +4.35%, while revenue for the quarter reached $2.67M , beating expectations by +19.00%.
NICXF Stock Performance
Access detailed NICXF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.